Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by scarlet1967on Oct 20, 2021 10:01am
125 Views
Post# 34026510

RE:RE:RE:RE:RE:Italy

RE:RE:RE:RE:RE:Italy

 

Wino115 wrote: I think we can go with Paul's "...it was a good price..." !  Certainly not US levels, but probably not below 50%.  It had always sounded to me like they thought they could get 75-80% of US price and the Viiv product provided a bit of an umbrella to that as well. 
 

SPCEO1 wrote: I think I will need to hire an Italian lawyer to actually figure out what the annual revenues from one Italian patient on Trogarzo for a year might be! They also mentioned discounts but it is not clear to me what those discounts might be and there seemed to be other circumstances that might impact the price. But figuring all that out seems like a lot of work and that you need to know someone familiar with Italian drug pricing to get an accurate answer. 

scarlet1967 wrote:

"packaging: «200 mg - concentrate for solution for infusion -

intravenous use - vial (glass) - 1.33 ml (150 mg / ml) »2

vials - AIC n. 048255018 / E (base 10);

    reimbursement class: H; 

    ex factory price (excluding VAT): euro 2,000.00; 

    retail price (VAT included): € 3,300.80.”


 




 

I don’t know what the reimbursement H class means versus retail price but 2000 euros equals US $2328. Compared with the US pricing excluding VAT(tax in Italy 22%) it seems it’s about 13% cheaper in Italy.

 

“The cost for Trogarzo intravenous solution (200 mg/1.33 mL) is around $2,671 for a supply of 2.66 milliliters.

The annual list price for every two-week infusions is $118,000.”

 

<< Previous
Bullboard Posts
Next >>